New Therapeutic Agents In Thrombosis And Thrombolysis, Revised And Expanded, Second Edition

Discussing the research on low-molecular-weight heparins, as well as agents such as pentasaccharide, TFP1, soluble thrombomodulin, and alfimeprase. This book details strategies to target conventional and characterized pathways of hemostasis. It is for cardiologists, internists, primary care physicians, vascular medicine specialists, and others.

---

Presents new chapters discussing the latest research on low-molecular-weight heparins, as well as agents such as pentasaccharide, TFP1, soluble thrombomodulin, and alfimeprase.

Completely revised and expanded throughout, New Therapeutic Agents in Thrombosis and Thrombolysis details strategies to
target conventional and recently characterized pathways of hemostasis

minimize the prothrombotic function of activated platelets

assess the biochemical and pharmacological effects of antithrombotic agents
and discusses

the use of animal models for determination of antithrombotic drug efficacy

antithrombotic therapy as a key component of cardiovascular disease management

the management of thromboembolic events in children and pregnant women
Supplemented with more than 2000 contemporary references, New Therapeutic Agents in Thrombosis and Thrombolysis is an authoritative source for cardiologists, internists, primary care physicians, vascular medicine specialists, cardiovascular and vascular surgeons, hematologists, pulmonologists, critical care physicians, pharmacologists, pharmaceutical researchers, and fellows, residents, and graduate and medical school students in these disciplines.